Biocon staffer jumps to death from office building in Bengaluru BENGALURU: A 26-year-old employee with Biocon allegedly jumped to his death from the fifth floor of the biopharmaceutical company ...

A 26-year-old employee of biopharmaceutical company Biocon died on Tuesday after falling from the fifth floor of the firm’s campus on Hosur Road in Electronics City Phase II, Bengaluru. Police have ...

Police said the circumstances leading to the incident are still under investigation. The deceased has been identified as Anantha Kumar, a resident of Banashankari in south Bengaluru, according to a ...

A 26-year-old man employed at biopharmaceutical firm Biocon died on Tuesday after reportedly falling from the fifth floor of the company’s premises located on Hosur Road in Electronics City Phase II, ...

Did our AI summary help? A 26-year-old employee of Biocon Biologics Limited allegedly died by suicide after falling from the fifth floor of the company building in Bengaluru on Tuesday, reported ...

The transaction accelerates the expiration of biosimilars non-compete restrictions, the company said. The shares are subject to a six-month lock up period. Transaction value will be subject to related ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

Viatris (VTRS) on Saturday said that it has entered into definitive agreements with Biocon for the sale of Viatris' equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Indian pharmaceuticals firm Biocon Ltd. will buy out minority shareholders in Biocon Biologics Ltd. via a mix of cash and shares in a deal that values the biosimilars unit at $5.5 billion. Biocon will ...

Biocon to acquire stakes via share swaps with Serum Institute, Tata Capital, Activ Pine Shreehas Tambe to lead combined entity as CEO, managing director Biocon reviewed IPO, merger options before ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...